Developer docs
API playgroundTry for free, no card

Search company profiles

CVRx

Full company profile

uuid0000hjp

Namestring
CVRx
Legal namestring
CVRx, Inc.
Websiteurl
barostim.com
Company typeenum
Public
Founded yearint
2001
Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
251–500
akta.pro rankint
HeadquartersMinneapolis, United States
HQ citystring
Minneapolis
HQ countrystring
United States
HQ regionstring
North America
Markets served

Serves global market

Offices9 records

Each record includes

City, Country, Type, Description, Source

Keyword5 values
heart failure neuromodulation, implantable pulse generator, baroreflex activation therapy, cardiac medical devices, heart failure treatment
Industry3 codes
PRIMARYHLAHAFAG
Mechanical Circulatory Support (VAD, IABP, ECMO)
Healthcare & Life Sciences/Medical Devices & Diagnostics/Cardiovascular Devices (Stents, Valves, Rhythm Management)
SECONDARYHLAHAFAL
Cardiac Assist & Heart Failure Therapies (Implantables, Neuromodulation)
Healthcare & Life Sciences/Medical Devices & Diagnostics/Cardiovascular Devices (Stents, Valves, Rhythm Management)
SECONDARYHLADAJAJ
Cardiac Rehabilitation Programs
Healthcare & Life Sciences/Elder Care & Long-Term Care/Rehabilitation & Post-Acute Care Centers (Inpatient/Outpatient)
NAICS code1 code
  • Electromedical and Electrotherapeutic Apparatus Manufacturing334510
SIC code1 code
  • Electromedical & Electrotherapeutic Apparatus3845
Product category
Heart Failure Neuromodulation Devices
Social media profiles1 record
GTM motion4 records

Each record includes

Type, Description, Source

Revenue model3 records
1Barostim system hardware sales
TypeHardware Sales
Description

Primary revenue from sale of the Barostim NEO2 implantable pulse generator, Carotid Sinus Lead, and Programmer to hospitals and heart failure treatment centers. Recognized as discrete unit sales recognized at implant / shipment.

globenewswire.com
2U.S. commercial revenue (geographic mix)
TypeHardware Sales
Description

U.S. revenue growth highlighted in quarterly results (Q1 2026 grew 22% in the United States); international/EU presence implied via cvrx.eu. Revenue mix is heavily U.S.-weighted with growth in US implanting centers.

globenewswire.com
3Reimbursement / patient access support services
TypeProfessional Services
Description

CV-Rx Prior Authorization Service (C-PAS) provides case-by-case coding, coverage, eligibility, prior auth, pre/post service appeals support bundled with device adoption; not a separate paid service but supports device sales funnel.

barostim.com
Marketing channels12 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels6 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components5 values
Personnel, Marketing or Sales, Technology or R&D, Operations, Others
Pricing details1 tier
1Quote-based hospital/center pricing, reimbursed via private insurance and CMS under CPT codes 64654-64659 (implant/revision/removal) and 93145/93146 (interrogation/ programming), effective Jan 1, 2026.
ModelOtherBilling cadencePay-as-you-go
Notes

Prior authorization generally required by most insurance plans; C-PAS provides coding, coverage verification, and appeals support. Reimbursement rates are set by payer fee schedules, not by CVRx.

barostim.com
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Brand1 of 4 records shown
1Barostim
Description

The company's flagship FDA-approved neuromodulation therapy system for heart failure symptoms.

barostim.com
+3 more records
Core offering1 text field

CVRx develops and commercializes the Barostim System, the first FDA-approved neuromodulation therapy indicated for heart failure symptoms. The Barostim System consists of an implantable pulse generator (current-generation Barostim NEO2, IPG model 2104), a Carotid Sinus Lead (model 1036) sutured to the carotid sinus, and a dedicated clinician-facing Programmer. The system delivers Baroreflex Activation Therapy (BAT) — continuous low-level electrical pulses to carotid baroreceptors — to rebalance autonomic nervous system tone in NYHA Class III (and Class II with recent Class III) heart failure patients with LVEF ≤35% despite guideline-directed medical therapy. CVRx also offers C-PAS, a HIPAA-compliant prior authorization and reimbursement support service bundled with the device.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 8 values shown
  • +60 yards (≈+44 meters) farther in 6-minute hall walk at 12 months (BeAT-HF)
+7 more records
Product overview1 text field

CVRx offers a single integrated medical-device platform, the Barostim System, rather than a multi-product SaaS portfolio. The platform architecture combines three named hardware components — the Barostim NEO2 IPG (current-generation implantable pulse generator, with the Barostim NEO and Barostim Legacy IPGs as prior generations), the Carotid Sinus Lead, and the clinician-facing Programmer — which together deliver Baroreflex Activation Therapy (BAT), CVRx's core neuromodulation therapy for heart failure symptoms. Layered on top of this device platform is C-PAS (CVRx Prior Authorization Service), a reimbursement support service that assists healthcare professionals with insurance approval and coding/billing for the Barostim implant procedure. The Barostim System is the first and only FDA-approved neuromodulation technology indicated for heart failure symptoms (NYHA Class III, and Class II with recent Class III history), and the components fit together as follows: the Carotid Sinus Lead is implanted on the carotid sinus and receives stimulation pulses from the Barostim NEO2 IPG; the Programmer is used by clinicians to interrogate and adjust the IPG; and C-PAS provides the commercial/reimbursement workflow that supports patient access to the system.

Product and service3 records
1Barostim System
CategoryHeart Failure Neuromodulation Devices
Description

The Barostim System is CVRx's flagship neuromodulation therapy platform for the treatment of advanced heart failure symptoms in adults who remain symptomatic (NYHA Class III or Class II with recent Class III history) on guideline-directed medical therapy, with LVEF ≤35%. The system delivers Baroreflex Activation Therapy (BAT) via an implantable pulse generator (current-generation Barostim NEO2 IPG model 2104) and a Carotid Sinus Lead (model 1036) sutured to the carotid sinus, programmed by a clinician-facing Programmer. It is the first and only FDA-approved neuromodulation technology indicated for heart failure symptoms and is sold to U.S. hospitals and heart failure treatment centers.

2Barostim NEO2 IPG (Implantable Pulse Generator)
CategoryImplantable Medical Device Component
Description

The Barostim NEO2 is the current-generation Implantable Pulse Generator (IPG model 2104) of the Barostim System. It delivers continuous low-level electrical stimulation to carotid baroreceptors through the Carotid Sinus Lead, has an FDA MR Conditional safety label (magnetic switch auto-pauses therapy during MRI), and supports a 5–6 year battery life. It is sold to hospitals and implanting centers as the next-generation commercial IPG of the Barostim System.

3C-PAS (CVRx Prior Authorization Service)
CategoryReimbursement and Patient Access Service
Description

C-PAS is CVRx's HIPAA-compliant in-house prior authorization service that supports healthcare professionals through the insurance approval workflow for the Barostim System. C-PAS provides case-by-case coding, coverage verification, eligibility, prior authorization, and pre/post-service appeals support to operationalize reimbursement and enable hospital-level adoption.

Scale indicator12 records

Each record includes

Type, Value, Description, Source

Recent move6 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight6 records

Each record includes

Type, Description

Peers10 records
TypeDirect peer
Description

Small-cap U.S. neuromodulation medtech commercializing an implantable neurostimulation system (for OSA). Highly comparable to CVRx as a single-platform, implantable neuromodulation company selling direct-to-physician with similar reimbursement and prior-authorization dynamics.

2Axonics
TypeDirect peer
Description

Commercial-stage neuromodulation company developing implantable sacral nerve stimulation devices for incontinence. Comparable as a focused, single-therapy implantable neuromodulation business with similar sales-rep-driven adoption model in physician offices.

TypeDirect peer
Description

Neuromodulation company commercializing spinal cord stimulation systems for chronic pain. Comparable as a small-cap implantable neurostim company with similar reimbursement code dependencies and direct-to-physician sales motion.

TypeEmerging player
Description

Respicardia developed an implantable neuromodulation system (remedē) targeting central sleep apnea, now part of ZOLL. Most directly comparable as a competing implantable neuromodulation therapy in adjacent cardiovascular/pulmonary indications with overlapping cardiology call points.

TypeEmerging player
Description

Clinical-stage company developing cardiac neuromodulation therapies (including a renal denervation program for hypertension). Comparable as a developer of device-based neuromodulation targeting cardiovascular indications with overlapping physician specialties.

TypeBroad incumbent
Description

Global medtech with neuromodulation (VNS for epilepsy/depression) and cardiovascular (heart-lung machines, oxygenators) franchises. Comparable as a larger incumbent with overlapping cardiac surgery/neuromodulation capabilities relevant to Barostim's call points.

TypeBroad incumbent
Description

Largest pure-play medtech with deep cardiac device franchises (CRT-Ds, ICDs, heart failure diagnostics like CardioMEMS). Comparable as a broad incumbent whose HF portfolio and CRM sales infrastructure shape the competitive landscape Barostim navigates.

8Abbott
TypeBroad incumbent
Description

Major cardiovascular device manufacturer with HF (CardioMEMS), CRM, and structural heart franchises. Comparable as the broad incumbent whose former executives now lead CVRx's commercial and medical organizations.

TypeBroad incumbent
Description

Major cardiovascular medtech with CRM, interventional cardiology, and structural heart businesses. Comparable as a broad incumbent; Board Chair Kevin Ballinger was previously EVP/Global President of Interventional Cardiology at Boston Scientific.

TypeBroad incumbent
Description

Focused structural heart and critical care medtech incumbent. Comparable as a larger incumbent in advanced cardiovascular therapy with overlapping heart failure specialist relationships and hospital economic buyer dynamics.

Market position
Strengths4 records

Each record includes

Headline, Details, Source

Weaknesses4 records

Each record includes

Headline, Details, Source

Competitive moat6 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights6 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers9 records

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment4 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile1 record

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature6 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles15 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
Compliance8 records

Each record includes

Name, Class, Description

Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds9 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors22 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

CVRx

Heart Failure Neuromodulation Devicesbarostim.com

CVRx firmographics

Firmographics
Name
CVRx
Legal name
CVRx, Inc.
Website
https://barostim.com
Company type
Public
Founded year
2001
Operating status
Operating
Headcount range
251–500 employees
Ownership category
akta.pro rank

CVRx industry classification

Industry
Product category
Heart Failure Neuromodulation Devices
NAICS
Electromedical and Electrotherapeutic Apparatus Manufacturing (334510)
SIC
Electromedical & Electrotherapeutic Apparatus (3845)
akta.pro industry
PRIMARYHLAHAFAG
Mechanical Circulatory Support (VAD, IABP, ECMO)
Healthcare & Life Sciences/Medical Devices & Diagnostics/Cardiovascular Devices (Stents, Valves, Rhythm Management)
SECONDARYHLAHAFAL
Cardiac Assist & Heart Failure Therapies (Implantables, Neuromodulation)
Healthcare & Life Sciences/Medical Devices & Diagnostics/Cardiovascular Devices (Stents, Valves, Rhythm Management)
SECONDARYHLADAJAJ
Cardiac Rehabilitation Programs
Healthcare & Life Sciences/Elder Care & Long-Term Care/Rehabilitation & Post-Acute Care Centers (Inpatient/Outpatient)

Keywords

  • Heart failure neuromodulation
  • Implantable pulse generator
  • Baroreflex activation therapy
  • Cardiac medical devices
  • Heart failure treatment

Where CVRx is headquartered

Location

Headquarters

HQ city
Minneapolis
HQ country
United States
HQ region
North America

Offices9 records

Markets served

CVRx business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Personnel, Marketing or Sales, Technology or R&D, Operations, Others

Revenue model

  1. Barostim system hardware sales: Primary revenue from sale of the Barostim NEO2 implantable pulse generator, Carotid Sinus Lead, and Programmer to hospitals and heart failure treatment centers. Recognized as discrete unit sales recognized at implant / shipment.
  2. U.S. commercial revenue (geographic mix): U.S. revenue growth highlighted in quarterly results (Q1 2026 grew 22% in the United States); international/EU presence implied via cvrx.eu. Revenue mix is heavily U.S.-weighted with growth in US implanting centers.
  3. Reimbursement / patient access support services: CV-Rx Prior Authorization Service (C-PAS) provides case-by-case coding, coverage, eligibility, prior auth, pre/post service appeals support bundled with device adoption; not a separate paid service but supports device sales funnel.

Pricing tiers

ModelBillingPrice
OtherPay-as-you-goQuote-based hospital/center pricing, reimbursed via private insurance and CMS under CPT codes 64654-64659 (implant/revision/removal) and 93145/93146 (interrogation/ programming), effective Jan 1, 2026.

Go-to-market motion4 records

Distribution channels6 records

Marketing channels12 records

CVRx product offering

Product offering

Core offering

CVRx develops and commercializes the Barostim System, the first FDA-approved neuromodulation therapy indicated for heart failure symptoms. The Barostim System consists of an implantable pulse generator (current-generation Barostim NEO2, IPG model 2104), a Carotid Sinus Lead (model 1036) sutured to the carotid sinus, and a dedicated clinician-facing Programmer. The system delivers Baroreflex Activation Therapy (BAT) — continuous low-level electrical pulses to carotid baroreceptors — to rebalance autonomic nervous system tone in NYHA Class III (and Class II with recent Class III) heart failure patients with LVEF ≤35% despite guideline-directed medical therapy. CVRx also offers C-PAS, a HIPAA-compliant prior authorization and reimbursement support service bundled with the device.

Product overview

CVRx offers a single integrated medical-device platform, the Barostim System, rather than a multi-product SaaS portfolio. The platform architecture combines three named hardware components — the Barostim NEO2 IPG (current-generation implantable pulse generator, with the Barostim NEO and Barostim Legacy IPGs as prior generations), the Carotid Sinus Lead, and the clinician-facing Programmer — which together deliver Baroreflex Activation Therapy (BAT), CVRx's core neuromodulation therapy for heart failure symptoms. Layered on top of this device platform is C-PAS (CVRx Prior Authorization Service), a reimbursement support service that assists healthcare professionals with insurance approval and coding/billing for the Barostim implant procedure. The Barostim System is the first and only FDA-approved neuromodulation technology indicated for heart failure symptoms (NYHA Class III, and Class II with recent Class III history), and the components fit together as follows: the Carotid Sinus Lead is implanted on the carotid sinus and receives stimulation pulses from the Barostim NEO2 IPG; the Programmer is used by clinicians to interrogate and adjust the IPG; and C-PAS provides the commercial/reimbursement workflow that supports patient access to the system.

Differentiator

Problem solved

Functional benefit

Brands

  • Barostim: The company's flagship FDA-approved neuromodulation therapy system for heart failure symptoms.
  • Barostim NEO2
  • Barostim NEO
  • BAT (Baroreflex Activation Therapy)

Products and services

  • Barostim System The Barostim System is CVRx's flagship neuromodulation therapy platform for the treatment of advanced heart failure symptoms in adults who remain symptomatic (NYHA Class III or Class II with recent Class III history) on guideline-directed medical therapy, with LVEF ≤35%. The system delivers Baroreflex Activation Therapy (BAT) via an implantable pulse generator (current-generation Barostim NEO2 IPG model 2104) and a Carotid Sinus Lead (model 1036) sutured to the carotid sinus, programmed by a clinician-facing Programmer. It is the first and only FDA-approved neuromodulation technology indicated for heart failure symptoms and is sold to U.S. hospitals and heart failure treatment centers.
  • Barostim NEO2 IPG (Implantable Pulse Generator) The Barostim NEO2 is the current-generation Implantable Pulse Generator (IPG model 2104) of the Barostim System. It delivers continuous low-level electrical stimulation to carotid baroreceptors through the Carotid Sinus Lead, has an FDA MR Conditional safety label (magnetic switch auto-pauses therapy during MRI), and supports a 5–6 year battery life. It is sold to hospitals and implanting centers as the next-generation commercial IPG of the Barostim System.
  • C-PAS (CVRx Prior Authorization Service) C-PAS is CVRx's HIPAA-compliant in-house prior authorization service that supports healthcare professionals through the insurance approval workflow for the Barostim System. C-PAS provides case-by-case coding, coverage verification, eligibility, prior authorization, and pre/post-service appeals support to operationalize reimbursement and enable hospital-level adoption.

Quantifiable outcome

  • +60 yards (≈+44 meters) farther in 6-minute hall walk at 12 months (BeAT-HF)
  • +7 more outcomes

Companies that use CVRx

Customer profile

Named customers9 records

Segments4 records

Ideal customer profiles1 record

CVRx technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature6 records

CVRx partnerships and signals

Strategic signal

Scale indicators12 records

Recent moves6 records

Expansion highlights6 records

CVRx competitors and assessment

Company assessment

Direct peers

  • Inspire Medical Systems: Small-cap U.S. neuromodulation medtech commercializing an implantable neurostimulation system (for OSA). Highly comparable to CVRx as a single-platform, implantable neuromodulation company selling direct-to-physician with similar reimbursement and prior-authorization dynamics.
  • Axonics: Commercial-stage neuromodulation company developing implantable sacral nerve stimulation devices for incontinence. Comparable as a focused, single-therapy implantable neuromodulation business with similar sales-rep-driven adoption model in physician offices.
  • Nevro: Neuromodulation company commercializing spinal cord stimulation systems for chronic pain. Comparable as a small-cap implantable neurostim company with similar reimbursement code dependencies and direct-to-physician sales motion.

Emerging players

  • Respicardia / ZOLL Medical: Respicardia developed an implantable neuromodulation system (remedē) targeting central sleep apnea, now part of ZOLL. Most directly comparable as a competing implantable neuromodulation therapy in adjacent cardiovascular/pulmonary indications with overlapping cardiology call points.
  • Orchestra BioMed: Clinical-stage company developing cardiac neuromodulation therapies (including a renal denervation program for hypertension). Comparable as a developer of device-based neuromodulation targeting cardiovascular indications with overlapping physician specialties.

Broad incumbents

  • LivaNova: Global medtech with neuromodulation (VNS for epilepsy/depression) and cardiovascular (heart-lung machines, oxygenators) franchises. Comparable as a larger incumbent with overlapping cardiac surgery/neuromodulation capabilities relevant to Barostim's call points.
  • Medtronic: Largest pure-play medtech with deep cardiac device franchises (CRT-Ds, ICDs, heart failure diagnostics like CardioMEMS). Comparable as a broad incumbent whose HF portfolio and CRM sales infrastructure shape the competitive landscape Barostim navigates.
  • Abbott: Major cardiovascular device manufacturer with HF (CardioMEMS), CRM, and structural heart franchises. Comparable as the broad incumbent whose former executives now lead CVRx's commercial and medical organizations.
  • Boston Scientific: Major cardiovascular medtech with CRM, interventional cardiology, and structural heart businesses. Comparable as a broad incumbent; Board Chair Kevin Ballinger was previously EVP/Global President of Interventional Cardiology at Boston Scientific.
  • Edwards Lifesciences: Focused structural heart and critical care medtech incumbent. Comparable as a larger incumbent in advanced cardiovascular therapy with overlapping heart failure specialist relationships and hospital economic buyer dynamics.

Market position

Strengths4 records

Weaknesses4 records

Competitive moat6 records

Key risks6 records

Key highlights6 records

Customer concentration

CVRx social profiles

Digital presence

CVRx compliance and trust

Trust signal

Compliance8 records

CVRx financial estimates

Financial estimate

Revenue estimate

Valuation estimate

CVRx leadership team

Management profile

Number of profiles

Profiles15 records

CVRx funding detail

Funding detail

Funding overview

Funding rounds9 records

Investors22 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

CVRx M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about CVRx

What does CVRx do?

CVRx develops and commercializes the Barostim System, the first FDA-approved neuromodulation therapy indicated for heart failure symptoms. The Barostim System consists of an implantable pulse generator (current-generation Barostim NEO2, IPG model 2104), a Carotid Sinus Lead (model 1036) sutured to the carotid sinus, and a dedicated clinician-facing Programmer. The system delivers Baroreflex Activation Therapy (BAT) — continuous low-level electrical pulses to carotid baroreceptors — to rebalance autonomic nervous system tone in NYHA Class III (and Class II with recent Class III) heart failure patients with LVEF ≤35% despite guideline-directed medical therapy. CVRx also offers C-PAS, a HIPAA-compliant prior authorization and reimbursement support service bundled with the device.

Is CVRx a public or private company?

CVRx is a public company. It is classified as public and is currently operating.

When was CVRx founded?

CVRx was founded in 2001. It employs 251 to 500 people.

Where is CVRx based?

CVRx is headquartered in Minneapolis, United States, in the North America region.

How does CVRx make money?

Three revenue lines are on record. Barostim system hardware sales are the primary driver. The others are U.S. commercial revenue (geographic mix) and reimbursement / patient access support services.

Who are CVRx's main competitors?

Direct peers on record are Inspire Medical Systems, Axonics and Nevro. Emerging players are Respicardia / ZOLL Medical and Orchestra BioMed. Broad incumbents are LivaNova, Medtronic, Abbott, Boston Scientific and Edwards Lifesciences.

Does CVRx have an API?

No public API is recorded for CVRx.

What industry is CVRx in?

CVRx's product category is Heart Failure Neuromodulation Devices. Its primary akta.pro industry code is HLAHAFAG, Mechanical Circulatory Support (VAD, IABP, ECMO), with a secondary code of HLAHAFAL, Cardiac Assist & Heart Failure Therapies (Implantables, Neuromodulation). Its NAICS code is 334510 and its SIC code is 3845.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
FinancialContent Business PageCVRX INVESTORS: Contact Kirby McInerney LLP About the Securities Fraud Lawsuit Filed on Behalf of CVRx, Inc. ShareholdersKirby McInerney LLP is seeking investors to contact about a securities fraud class action against CVRx, alleging illegal sales practices and false claims. The suit covers purchases from July 25, 2023 to August 6, 2026, and follows a DOJ civil investigative demand that caused CVRx's stock to fall 60% to $2.39.The future of tradingCVRX DEADLINE: Levi & Korsinsky Reminds CVRx, Inc. Investors of Upcoming Securities Class Action DeadlineLevi & Korsinsky announced a securities class action lawsuit against CVRx, Inc. seeking recovery for investors who suffered losses from alleged securities fraud between July 25, 2023 and August 6, 2026. The complaint alleges false statements about illegal sales practices, kickbacks, and compliance with the False Claims Act and Anti-Kickback Statute.FinancialContent Business PageINVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in CVRx, Inc. of Class Action Lawsuit and Upcoming Deadlines – CVRXPomerantz LLP notified CVRx investors of a securities fraud class action, urging them to contact the firm. Investors have until January 8, 2027, to seek lead plaintiff appointment. The suit alleges unlawful business practices, and CVRx's stock has fallen significantly since Q1 2025.GlobeNewswireINVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in CVRx, Inc. of Class Action Lawsuit and Upcoming Deadlines – CVRXPomerantz LLP notified investors with CVRx losses of a class action lawsuit alleging securities fraud. The suit cites CVRx's Q1 2025 revenue miss and a DOJ civil investigative demand, with a January 8, 2027 deadline for lead plaintiff appointment.AktienROSEN, A RANKED AND LEADING LAW FIRM, Encourages CVRx, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - CVRXRosen Law Firm announced a securities class action against CVRx, Inc. for alleged false statements about revenue growth, sales practices, and regulatory compliance. The lawsuit covers purchases from July 25, 2023 to August 6, 2026, with a lead plaintiff deadline of January 8, 2027. Investors may seek compensation via contingency fee.The future of tradingROSEN, A RANKED AND LEADING LAW FIRM, Encourages CVRx, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - CVRXRosen Law Firm announced a securities class action against CVRx, Inc. for alleged false statements about revenue growth, sales practices, and regulatory compliance. The lawsuit covers purchases from July 25, 2023 to August 6, 2026, with a lead plaintiff deadline of January 8, 2027. No class has been certified yet.FinancialContent Business PageDid You Lose Money Investing in CVRx, Inc.? Robbins LLP Urges Investors with Significant Losses to Contact the Firm for Information About Their Rights Against CVRXRobbins LLP urged CVRx investors to contact the firm about a securities class action filed for purchases between July 25, 2023 and August 6, 2026. The complaint alleges CVRx misled investors about illegal sales practices, including kickbacks and false claims to government programs, and a DOJ civil investigative demand. Investors have until January 8, 2027 to seek lead plaintiff appointment.GlobeNewswireROSEN, GLOBAL INVESTOR COUNSEL, Encourages CVRx, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - CVRXRosen Law Firm announced a securities class action against CVRx, Inc. for alleged false statements about revenue growth, sales practices, and regulatory compliance. The lawsuit claims improper sales practices, including kickbacks and false information to government programs, and sets a lead plaintiff deadline of January 8, 2027.AktienROSEN, A LEADING INVESTOR RIGHTS LAW FIRM, Encourages CVRx, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - CVRXRosen Law Firm announced a securities class action against CVRx, Inc. for alleged false statements about revenue growth, sales practices, and regulatory compliance. The lawsuit covers purchases from July 25, 2023 to August 6, 2026, with a lead plaintiff deadline of January 8, 2027. Investors may seek compensation via contingency fee arrangement.